Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model.
about
Effect of atypical antipsychotics on fetal growth: is the placenta involved?An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineMetabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in ratsOlanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatmentAcute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistanceRecent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Clozapine modifies the differentiation program of human adipocytes inducing browning.Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain.Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.Atypical antipsychotics and diabetic ketoacidosis: a review.Acute hyperglycemia associated with short-term use of atypical antipsychotic medications.Atypical antipsychotic-induced metabolic disturbances in the elderly.An Overview of Links Between Obesity and Mental Health.Depot risperidone-induced adverse metabolic alterations in female rats.In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats.Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice.Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
P2860
Q27012948-C738853C-9B25-4123-B1FF-551A236719DEQ28543222-85567A45-52E3-441B-BDFA-B24EB60596C3Q30459096-4CED911B-E80A-4863-AAF0-BB11A368B0F6Q33765864-FEF0B7E6-091E-488D-B869-FAA9F4E5BA3CQ33942644-0C1F8314-F2C2-438E-A43F-9076CA07CB46Q34033259-023A19F2-FF39-4EB2-9AEB-5137C9413295Q34117015-D23CF176-FEC9-454C-AA40-AC32E30159EFQ34376884-184C1765-C84B-489E-8D44-80411DA8345CQ34506022-D26FC161-FF39-45E6-B6F6-CD93D4F51B7DQ35675775-1F24B94A-D4B6-417B-9D6F-41C595F74CC3Q35757166-BDE4D680-FB3C-45EC-9597-D084C5892B5CQ36063735-71B4187D-F784-41F0-BB73-EBCBEF5456ADQ36206591-CD1045EA-13E0-4775-BD84-A8CBB670EF4FQ36383322-13283529-EF96-45D2-B006-7B1F1946E18CQ36408212-36111000-1A4E-4E83-8A65-A6BCDA0757B4Q36593819-7A515EBE-BB0C-4082-8566-D827698BFB81Q37698621-072B6771-926F-43F0-B746-9087B1AB65F2Q38076320-35EED900-6EE8-4751-8F46-A87A1AECA6F1Q38176569-0AB4E1D3-D72B-497B-9163-0924806056C0Q38183274-E76A26B9-495F-4A5B-B7CD-7AECBCDE24C2Q38655964-5DC342F1-296B-423B-92FA-8DD989A4F6E4Q38873420-17B441F2-B866-4C63-B6C4-BE16EC8B3473Q43090127-333BA3ED-59DF-4E64-B67B-30084575CEB0Q47165661-C9BB31DC-74A5-4D69-80B8-8DEF63929DB2Q47359953-7D6DC981-5510-4DA1-9AF6-E86348436D8EQ47596558-18F935B5-5ABD-4C0A-84F5-DF7322E861BDQ47762878-36C98F99-319D-4583-9DD5-FA696EC56C5EQ49456987-1858B626-C815-4F0D-8FA6-F2F2EEEC37ADQ50773348-AD22F4C0-BD04-4816-8CD8-3FE361B654A6
P2860
Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Insulin resistance and secreti ...... psychotics in an animal model.
@en
Insulin resistance and secreti ...... psychotics in an animal model.
@nl
type
label
Insulin resistance and secreti ...... psychotics in an animal model.
@en
Insulin resistance and secreti ...... psychotics in an animal model.
@nl
prefLabel
Insulin resistance and secreti ...... psychotics in an animal model.
@en
Insulin resistance and secreti ...... psychotics in an animal model.
@nl
P2093
P50
P1476
Insulin resistance and secreti ...... psychotics in an animal model.
@en
P2093
Araba F Chintoh
Jose Nobrega
Paul Fletcher
Steve W Mann
P304
P356
10.1016/J.SCHRES.2008.12.012
P407
P577
2009-01-20T00:00:00Z